| scholarly article | Q13442814 |
| P50 | author | Paul Haluska | Q87036002 |
| P2093 | author name string | Clare L Scott | |
| Helen J Mackay | |||
| P2860 | cites work | Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization | Q23921272 |
| Orthotopic Xenograft Model of Cervical Cancer for Studying Microenvironmental Effects on Metastasis Formation and Response to Drug Treatment | Q61872230 | ||
| The kinetics of recovery in irradiated colonic mucosa of the mouse | Q69817031 | ||
| Preclinical phase II studies in human tumor xenografts: a European multicenter follow-up study | Q72160214 | ||
| Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group | Q73507149 | ||
| Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix | Q73675166 | ||
| HEIGHTENED IMMUNITY AND SUSCEPTIBILITY TOWARD CHEEK POUCH HETEROGRAFTS OF A MOUSE LEUKEMIA IN SYRIAN HAMSTERS | Q76617591 | ||
| Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer | Q77321070 | ||
| Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer | Q77321076 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models | Q81120942 | ||
| Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats | Q81310319 | ||
| Commentary on the clinical trial reported by: Tewari KS, Sill M, Long III HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group. J Clin On | Q87054592 | ||
| Patient-derived tumour xenografts as models for oncology drug development | Q24604068 | ||
| Efficient tumour formation by single human melanoma cells | Q24648938 | ||
| Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment | Q26829125 | ||
| One mouse, one patient paradigm: New avatars of personalized cancer therapy | Q27023342 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Phenotypic instability of Saos-2 cells in long-term culture | Q28254879 | ||
| Integrated genomic characterization of endometrial carcinoma | Q28289962 | ||
| Wnt activity defines colon cancer stem cells and is regulated by the microenvironment | Q29618024 | ||
| BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation | Q33930051 | ||
| Landscape of genomic alterations in cervical carcinomas | Q34169464 | ||
| Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability. | Q34490295 | ||
| Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells | Q34836634 | ||
| Pathway-specific differences between tumor cell lines and normal and tumor tissue cells | Q35129156 | ||
| Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts | Q35448716 | ||
| Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures | Q36899265 | ||
| Evaluation of early and late toxicities in chemoradiation trials. | Q36935098 | ||
| Hormonal therapies and gynaecological cancers | Q36947766 | ||
| Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx) | Q37017045 | ||
| Evaluating cell lines as tumour models by comparison of genomic profiles | Q37025950 | ||
| Tumorgrafts as in vivo surrogates for women with ovarian cancer. | Q37626455 | ||
| Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix | Q37678092 | ||
| Hepatobiliary cystadenoma with mesenchymal stroma | Q38137801 | ||
| The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy | Q38163007 | ||
| Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype | Q40084367 | ||
| Development of a quantitative Correlative Light Electron Microscopy technique to study GLUT4 trafficking | Q41609333 | ||
| Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors | Q41727237 | ||
| Establishment of a cell line (Co-115) from a human colon carcinoma transplanted into nude mice | Q42039616 | ||
| Biological Characterization of Human Epithelial Ovarian Carcinoma Cells in Primary Culture: The Insulin-like Growth Factor System | Q42817129 | ||
| Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. | Q44308450 | ||
| Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy | Q46244368 | ||
| Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study | Q46494607 | ||
| Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study | Q46630310 | ||
| A human ovarian carcinoma murine xenograft model useful for preclinical trials | Q46787985 | ||
| Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation | Q54342333 | ||
| The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. | Q54632436 | ||
| Response of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle | Q54753977 | ||
| Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy | Q60043794 | ||
| P921 | main subject | patient | Q181600 |
| xenograft | Q64148587 | ||
| P304 | page(s) | e258-66 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | American Society of Clinical Oncology educational book / ASCO | Q26842316 |
| P1476 | title | Patient-derived xenograft models in gynecologic malignancies |
| Q58549406 | A patient derived xenograft model of cervical cancer and cervical dysplasia |
| Q37558633 | A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers |
| Q36750564 | Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. |
| Q37272622 | Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma |
| Q98777898 | Human-Derived Model Systems in Gynecological Cancer Research |
| Q38705019 | Modeling of Patient-Derived Xenografts in Colorectal Cancer |
| Q38508812 | Ovarian and cervical cancer patient derived xenografts: The past, present, and future. |
| Q36414048 | Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure |
| Q58768056 | Patient-Derived Xenograft Models for Endometrial Cancer Research |
| Q33842769 | Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts |
| Q36326279 | The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin |
| Q35771750 | The promise and challenge of ovarian cancer models |
| Q35586693 | The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience |
| Q38257126 | Translational research in oncology--10 years of progress and future prospects |
Search more.